Boehringer Ingelheim (BI's) -- the German pharmaceutical company -- has just completed the first-ever full bore social media campaign touting the results of its RE-LY® study - "the largest atrial fibrillation (AF) outcomes trial ever conducted." The results of the study were presented for the first time at the European Society of Cardiology (ESC) Congress yesterday. BI live-tweeted from the RELY press briefing and presentation in Barcelona.
The Tweets included statements like:
- "RELY dabigatran had no liver toxicity" [Pradaxa® (dabigatran etexilate) is BI's brand anti-coagulant drug that competes with generic warfarin]
- "RE-LY results: Significance on primary endpoints and significantly lower bleeding"
BI also used Twitpic to show us that "Demand is high to get into the RELY press briefing" (see photo).
Not only has BI used the free services of Twitter and Twitpic to promote the results of this clinical trial, it also uploaded new videos on its new new Boehringer Stroke Prevention YouTube channel.
On August 27, 2009 it uploaded the video entitled "Day in the life of a Warfarin patient," which has an actor portraying a patient who complains about the problems he has with warfarin treatment.
As promised, the YouTube channel is also "packed with RE-LY trial information."
That's a lot of promotion for very little money!
BI seems to be ahead of the pharma pack in using social media to woo journalists and physicians rather than the general public via Twitter and other social media. I discussed this strategy with Judith von Gordon, BI's Head of External Communications, and John Pugh, BI's Director of Corporate Communication/External Communications, in a June, 2009 Pharma Marketing Talk podcast (see "Boehringer Ingelheim Pharma on Twitter: Boehringer Ingelheim").